H.W. Herr

6.1k total citations
82 papers, 4.4k citations indexed

About

H.W. Herr is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, H.W. Herr has authored 82 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Surgery, 23 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in H.W. Herr's work include Bladder and Urothelial Cancer Treatments (47 papers), Urinary and Genital Oncology Studies (29 papers) and Testicular diseases and treatments (19 papers). H.W. Herr is often cited by papers focused on Bladder and Urothelial Cancer Treatments (47 papers), Urinary and Genital Oncology Studies (29 papers) and Testicular diseases and treatments (19 papers). H.W. Herr collaborates with scholars based in United States, Netherlands and Brazil. H.W. Herr's co-authors include Howard I. Scher, Pramod C. Sogani, William R. Fair, Dean F. Bajorin, Willet F. Whitmore, Zuo‐Feng Zhang, Joel Sheinfeld, George J. Bosl, Guido Dalbagni and Robert J. Motzer and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

H.W. Herr

78 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.W. Herr United States 36 3.7k 1.1k 895 826 772 82 4.4k
Giorgio Pizzocaro Italy 33 3.3k 0.9× 902 0.8× 790 0.9× 438 0.5× 925 1.2× 133 4.0k
Roberto Salvioni Italy 32 2.3k 0.6× 904 0.8× 1.0k 1.2× 468 0.6× 277 0.4× 186 3.3k
Michael J. Morse United States 19 2.4k 0.6× 889 0.8× 330 0.4× 664 0.8× 442 0.6× 32 2.9k
Nicola Nicolai Italy 29 2.4k 0.6× 771 0.7× 526 0.6× 302 0.4× 416 0.5× 159 2.8k
Howard S. Levin United States 37 1.4k 0.4× 2.0k 1.9× 667 0.7× 367 0.4× 371 0.5× 90 3.5k
F.K. Mostofi United States 27 1.2k 0.3× 1.4k 1.3× 705 0.8× 288 0.3× 177 0.2× 48 2.6k
Melvin L. Samuels United States 28 1.5k 0.4× 1.1k 1.0× 483 0.5× 614 0.7× 80 0.1× 44 2.5k
Robin C. Watson United States 26 2.5k 0.7× 1.1k 1.0× 368 0.4× 1.0k 1.2× 251 0.3× 65 3.4k
Daniele Raggi Italy 26 1.5k 0.4× 540 0.5× 352 0.4× 596 0.7× 234 0.3× 177 2.0k
William R. Hart United States 44 1.9k 0.5× 1.0k 1.0× 562 0.6× 882 1.1× 139 0.2× 108 5.3k

Countries citing papers authored by H.W. Herr

Since Specialization
Citations

This map shows the geographic impact of H.W. Herr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.W. Herr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.W. Herr more than expected).

Fields of papers citing papers by H.W. Herr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.W. Herr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.W. Herr. The network helps show where H.W. Herr may publish in the future.

Co-authorship network of co-authors of H.W. Herr

This figure shows the co-authorship network connecting the top 25 collaborators of H.W. Herr. A scholar is included among the top collaborators of H.W. Herr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.W. Herr. H.W. Herr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moses, Kelvin A., Bernard H. Bochner, Derek Prabharasuth, et al.. (2013). Radical Cystectomy and Orthotopic Urinary Reconstruction in Patients With Bladder Cancer After Renal Transplantation: Clinical Outcomes and Description of Technique. Transplantation Proceedings. 45(4). 1661–1666. 12 indexed citations
2.
Herr, H.W.. (2003). Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality). British Journal of Urology. 92(3). 187–187. 29 indexed citations
3.
Herr, H.W.. (2000). Radiographic vs surgical size of renal tumours after partial nephrectomy. British Journal of Urology. 85(1). 19–21. 22 indexed citations
4.
Choi, So Yung, et al.. (1999). Sclerosing mesenteritis associated with skin panniculitis and pleural thickening.. The Korean Journal of Internal Medicine. 57(1). 103–107. 3 indexed citations
5.
Bajorin, Dean F., John A. McCaffrey, S Hilton, et al.. (1998). Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.. Journal of Clinical Oncology. 16(8). 2722–2727. 70 indexed citations
6.
Herr, H.W., et al.. (1998). Paternity in men with stage I testis tumors on surveillance.. Journal of Clinical Oncology. 16(2). 733–734. 29 indexed citations
7.
Herr, H.W., Dean F. Bajorin, & Howard I. Scher. (1998). Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.. Journal of Clinical Oncology. 16(4). 1298–1301. 143 indexed citations
8.
9.
Herr, H.W.. (1997). Quality of life in prostate cancer patients. CA A Cancer Journal for Clinicians. 47(4). 207–217. 67 indexed citations
10.
Brenner, Phillip, H.W. Herr, Michael J. Morse, et al.. (1996). Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.. Journal of Clinical Oncology. 14(6). 1765–1769. 65 indexed citations
11.
Motzer, Robert J., Joel Sheinfeld, Madhu Mazumdar, et al.. (1995). Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.. Journal of Clinical Oncology. 13(11). 2700–2704. 49 indexed citations
12.
Sarkis, A. S., Dean F. Bajorin, V E Reuter, et al.. (1995). Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.. Journal of Clinical Oncology. 13(6). 1384–1390. 195 indexed citations
13.
Schultz, Paul, H.W. Herr, Zuo‐Feng Zhang, et al.. (1994). Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.. Journal of Clinical Oncology. 12(7). 1394–1401. 116 indexed citations
14.
Herr, H.W.. (1994). Partial nephrectomy for incidental renal cell carcinoma. British Journal of Urology. 74(4). 431–433. 48 indexed citations
15.
Sarkis, A. S., Guido Dalbagni, C. Cordon‐Cardo, et al.. (1993). Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease Progression. JNCI Journal of the National Cancer Institute. 85(1). 53–59. 437 indexed citations
16.
Toner, Guy C., David M. Panicek, R T Heelan, et al.. (1990). Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.. Journal of Clinical Oncology. 8(10). 1683–1694. 199 indexed citations
17.
Scher, Howard I., H.W. Herr, William R. Fair, et al.. (1989). Neo‐adjuvant Chemotherapy for Invasive Bladder Cancer. Experience with the M‐VAC Regimen. British Journal of Urology. 64(3). 250–256. 85 indexed citations
18.
Herr, H.W., Vincent P. Laudone, Robert A. Badalament, et al.. (1988). Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.. Journal of Clinical Oncology. 6(9). 1450–1455. 234 indexed citations
19.
Bean, Michael A., et al.. (1978). Function of cryopreserved human effector cells in antibody-dependent, cell-mediated cytotoxicity.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 93–5.
20.
Herr, H.W., et al.. (1978). Cryptorchidism and testicular neoplasia.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 70(9). 659–64. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giorgio Pizzocaro Breakdown of academic impact, for papers by Roberto Salvioni Breakdown of academic impact, for papers by Michael J. Morse Breakdown of academic impact, for papers by Nicola Nicolai Breakdown of academic impact, for papers by Howard S. Levin Breakdown of academic impact, for papers by F.K. Mostofi Breakdown of academic impact, for papers by Melvin L. Samuels Breakdown of academic impact, for papers by Robin C. Watson Breakdown of academic impact, for papers by Daniele Raggi Breakdown of academic impact, for papers by William R. Hart
Rankless by CCL
2026